Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy.
Forty-nine patients undergoing mid-trimester extra-amniotic prostaglandin termination of pregnancy were studied. Twenty patients acted as controls and received the standard hospital regime. Twenty-nine patients received the same regime, but in addition were given a single 200-mg oral dose of the antiprogesterone, mifepristone (RU 486), 24 h prior to prostaglandin infusion. The dose of prostaglandin required and the induction to abortion interval in the mifepristone-pretreatment group was significantly reduced. Complication rates were similar in both groups. Mifepristone is a safe and useful adjuvant therapy in mid-trimester prostaglandin termination.
Urquhart
D R
DR
Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, UK.
Bahzad
C
C
Templeton
A A
AA
D000019:Abortifacient Agents / Q000494:pharmacology*; D000021:Abortifacient Agents, Steroidal / Q000494:pharmacology*; D000029:Abortion, Legal; D000328:Adult; D015232:Dinoprostone / Q000494:pharmacology*; D004341:Drug Evaluation; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015735:Mifepristone; D011247:Pregnancy; D011372:Progestins / Q000037:antagonists & inhibitors*
D000019:Abortifacient Agents; D000021:Abortifacient Agents, Steroidal; D004963:Estrenes; D011372:Progestins; D015735:Mifepristone; D015232:Dinoprostone